Wells Fargo keeps Buy rating for Viridian Therapeutics stock at USD 31 target

Published on 10/15/2026 at 12:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wells Fargo kept a Buy rating and a USD 31.00 target on October 14, 2026. Viridian Therapeutics stock costs EUR 16.40 on October 15, 2026.

Analyst view and operating context

Wells Fargo maintained a Buy rating and a USD 31.00 target on October 14, 2026.
Second-quarter 2026 revenue reached USD 284 thousand against a GAAP net loss of USD 127.12 million.
Viridian Therapeutics stock traded at EUR 16.40 at 12:39 p.m. CEST at Lang & Schwarz on October 15, 2026.

VRDN, US92790C1045, Illustration mit AI erstellt.

Viridian Therapeutics stock is tied to a USD 31.00 target after Wells Fargo maintained its Buy rating on October 14, 2026, according to Markets Insider. The biotechnology company is developing treatments for autoimmune and rare diseases, with thyroid eye disease as its immediate commercial focus, according to Viridian Therapeutics.

Target view meets thin revenue

The latest reported quarter ended June 30, 2026. Viridian posted USD 284 thousand in revenue and a GAAP net loss of USD 127.12 million, compared with USD 75 thousand of revenue and a GAAP net loss of USD 100.74 million in the year-earlier quarter, according to Markets Insider. The comparison shows commercial revenue was still at an early stage while development costs remained material.

Three targets mark the timeline

On October 2, 2026, LifeSci Capital maintained a USD 35.00 target, as reported by Markets Insider. On October 8, 2026, RBC Capital maintained a Buy rating with a USD 38.00 target. On October 14, 2026, Wells Fargo maintained a Buy rating with a USD 31.00 target, according to Markets Insider.

What date comes next?

MarketBeat estimates that Viridian will report third-quarter 2026 results on November 4, 2026, before the market opens. The same source lists consensus estimates of USD 4.58 million in revenue and a loss of USD 0.9717 per share.

Stock price and development pipeline

Viridian Therapeutics was trading at EUR 16.40 at Lang & Schwarz on October 15, 2026 at 12:39 p.m. CEST. Its pipeline includes Lumvoa, an FDA-approved treatment for thyroid eye disease, and elegrobart, an investigational subcutaneous therapy; a BLA submission for elegrobart is planned for the first quarter of 2027, according to Ophthalmology Times. The further course of trading is shown by the continuously updated real-time quote of Viridian Therapeutics stock.